FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

KATOPODIS ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/008436

FILED: 30 JULY 2003

U.S. APPLICATION NO: 10/522.823 35 USC §371 DATE: Not Yet Known

FOR: TOLERANCE INDUCTION WITH HELP OF A COMBINATION OF A LFA-1 INHIBITOR AND A COSTIMULATION INHIBITOR AND/OR A MTOR INHIBITOR

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed January 31, 2005. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. \$1,491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is a uested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants

Reg. No. 31,661

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7909

Date: July 8, 2005

- 2 -

FORM PTO-1449 U.S. DEP (REV. 7-85) PATENT INFORMATION DISCLOS

U.S. DEPARTMENT OF COMMERCE PATENT TRADEMARK OFFICE ISCLOS OF E CITATION

(Use several sheets if necessary)

ATTY. DOZET NO. TX/4-325 APPLICATE NO. 10/522,823 APPLICANT KATOPODIS ET AL. FILING DATE NOT YET KNOWN

Group

			U.S.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	ING DATE
	AA	2001/0055593	12/27/01	Sypek et al.	424	144.1	3/1:	3/01
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL							
			FOREIG	ON PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATION NO
	AM	01/15733	3/8/01	wo				
	AN	02/14865	2/21/02	wo				
	AO							
	AP							
	AQ							
		OTHER DOO	CUMENTS	(Including Author, Title, Date, Pe	ertinent pages, E	Etc.)		
-	AR	Förster et al., "Contri Transplantation, Vol.		40-CD154-Mediated Costin p. 1284-1287 (1999).	nulation to an	Alloresponse	in Vive	o",
	AS			ry Signals and T Cell Tolera edings, Vol. 31, Suppl. 1/2/			antatio	on
	_			Parameters in Human Rena	al Allograft Re	jection", Clini	cal	
	AT	Biochemistry, Vol. 34	, pp. 29-34 ((2001).				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE (REV. 7-85) PATENT TRADEMARK OFF INFORMATION DISCLOSSEE CITATION TRADEMARK OFFICE ATTY, DOGMET NO. TX/4-3258 APPLICA 10/522,823 APPLICANT KATOPODIS ET AL. FILING DATE

Not Yet Known

Sheet 2 of 2

Group

EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)					
	DA	Larsson et al., "Simultaneous Inhibition of B7 and LFA-1 Signaling Prevents Rejection of Discordant Neural Xenografts in Mice Lacking CD40L", Xenotransplantation, Vol. 9, pp. 68-76 (2002).				
	DB	Malm et al., "CTLA41G Induces Long-Term Graft Survival of Allogeneic Skin Grafts and Totally Inhibits T-Cell Proliferation in LFA-1-Deficient Mice", Transplantation, Vol. 73, No. 2, pp. 293-297 (2002).				
	DC	Waldmann, "Therapeutic Approaches for Transplantation", Current Opinion in Immunology, Vol. 13, pp. 606-610 (2001).				
	DD	Vincenti, "The Role of Newer Monoclonal Antibodies in Renal Transplantation", Transplantation Proceedings, Vol. 33, pp. 100-1001 (2001).				
	DE	Rayat et al., "Combination of Anti-LFA 1 Antibody with Anti-CD45RB or Anti-CD154 Antibody Promotes Long-Term Porcine Islet Xenograft Survival", Cell Transplantation, Vol. 10, No. 6, pp. 526-527 (2001).				
	DF					
	DG					
	DΗ					
	DI					
	DJ					
	DK					
	DL					
	DΜ					
	DN					
EXAMINE	Ŕ	/Michail Belyavskyi/ (07/13/2009) DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.